Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

36.65 +0.31 (+0.85%)

Streaming Delayed Price Updated: 9:48 AM EDT, Aug 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout ↗

June 22, 2023

The company is testing a treatment that blocks an inflammatory ligand in patients with ulcerative colitis.

Via Investor's Business Daily

Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period

June 22, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis

June 21, 2023

From Roivant Sciences

Via GlobeNewswire

5 Analysts Have This to Say About Roivant Sciences ↗

June 08, 2023

Via Benzinga

Why Shares of Roivant Sciences Jumped This Week ↗

April 20, 2023

The company's stock benefited from another company's buyout.

Via The Motley Fool

Analyst Expectations for Roivant Sciences's Future ↗

March 16, 2023

Via Benzinga

Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years ↗

March 15, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023 ↗

June 08, 2023

Via Benzinga

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission ↗

May 16, 2023

Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old...

Via Benzinga

Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

May 16, 2023

From Roivant Sciences

Via GlobeNewswire

Why Did Pfizer Offload This Potential Mega-Blockbuster Drug? ↗

April 23, 2023

Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so.

Via The Motley Fool

These 2 Growth Stocks Might Be Incredibly Undervalued Right Now ↗

April 20, 2023

These two biopharma stocks could be poised for a major growth spurt.

Via The Motley Fool

EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis ↗

April 17, 2023

While the 2024 U.S. presidential election may seem a long way off, polls to see who is favored by voters and betting odds for the next White House occupant have ramped up.

Via Benzinga

These 3 Nasdaq Stocks Are on Fire Today: Here's Why ↗

April 17, 2023

A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today.

Via The Motley Fool

Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom ↗

April 17, 2023

Merck is branching into immune-mediated diseases with this takeover.

Via Investor's Business Daily

Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

April 17, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93...

Via Benzinga

Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory

April 04, 2023

From Lokavant

Via Business Wire

Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research

April 04, 2023

From Lokavant

Via Business Wire

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗

March 29, 2023

For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.

Via InvestorPlace

Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients

March 28, 2023

From Covant Therapeutics

Via GlobeNewswire

Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 21, 2023

Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.

Via Benzinga

Why Shares of Roivant Sciences Were Down Tuesday ↗

March 21, 2023

After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains.

Via The Motley Fool

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

March 15, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis

March 14, 2023

From Roivant Sciences

Via GlobeNewswire

Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs

March 14, 2023

PVTX-321 and PVTX-405 Achieve Development Candidate Nomination

From Roivant Sciences

Via GlobeNewswire

Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement

March 07, 2023

From Roivant Sciences

Via GlobeNewswire

Roivant Sciences Announces Change to its Board of Directors

February 21, 2023

From Roivant Sciences

Via GlobeNewswire

Immunovant Could Potentially Be An M&A Target, Writes Analyst ↗

February 15, 2023

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.